Publications by authors named "Whitworth H"

Introduction: The pediatric direct oral anticoagulation (DOAC) trials provide an opportunity to evaluate and characterize challenges in their design and execution to inform future antithrombotic trials.

Objective: To perform a systematic review of pediatric DOAC trials for the treatment of venous thromboembolism to critically appraise their methodology and understand the feasibility and challenges.

Methods: Systematic search of MEDLINE, EMBASE, the Cochrane Library and ClinicalTrials.

View Article and Find Full Text PDF

: Orthoebolaviruses and orthomarburgviruses are filoviruses that can cause viral hemorrhagic fever and significant morbidity and mortality in humans. The evaluation and deployment of vaccines to prevent and control Ebola and Marburg outbreaks must be informed by an understanding of the transmission and natural history of the causative infections, but little is known about the burden of asymptomatic infection or undiagnosed disease. This systematic review of the published literature examined the seroprevalence of antibodies to orthoebolaviruses and orthomarburgviruses in sub-Saharan Africa.

View Article and Find Full Text PDF

Objectives: The purpose of this study was to describe the enoxaparin dose required by preterm neonates and infants to achieve therapeutic anti-Xa levels.

Study Design: Retrospective chart review of preterm infants, <12 weeks postnatal age, born before 37 weeks gestation, receiving subcutaneous (SUBQ) enoxaparin every 12 h (q12h) with an anti-Xa goal of 0.5-1 units/mL.

View Article and Find Full Text PDF

Background: Research in children is essential for them to benefit from the outcomes of research but involvement must be weighed against potential harms. In many countries and circumstances, medical research legally requires parental consent until the age of 18 years, with poorly defined recommendations for assent prior to this. However, there is little research exploring how these decisions are made by families and the ethical implications of this.

View Article and Find Full Text PDF

rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination.

View Article and Find Full Text PDF
Article Synopsis
  • Pediatric pulmonary embolism (PE) is uncommon but serious, with a study analyzing treatment methods and outcomes in U.S. pediatric hospitals from 2015 to 2021.
  • Approximately 88% of pediatric patients received anticoagulation alone for PE, while treatments like systemic thrombolysis and directed therapy were less common; directed therapy showed a lower mortality risk.
  • Additional research is needed to better understand pediatric PE due to the high occurrence of comorbidities in affected patients and the limitations of current treatment practices.
View Article and Find Full Text PDF

Objectives: This study systematically reviewed the published literature from clinical trials on the efficacy and immunogenicity of single-dose HPV vaccination compared to multidose schedules or no HPV vaccination.

Methods: Four databases were searched for relevant articles published from Jan-1999 to Feb-2023. Articles were assessed for eligibility for inclusion using pre-defined criteria.

View Article and Find Full Text PDF
Article Synopsis
  • - The KEN SHE trial demonstrated over 97% efficacy for a single-dose HPV vaccine against HPV16 and HPV18 infections in Kenyan women over 36 months.
  • - The DoRIS trial involved 930 Tanzanian girls aged 9-14, examining antibody responses from one, two, or three doses of either 2-valent (Cervarix) or 9-valent (Gardasil-9) vaccines, finding comparable or higher antibody levels at 24 months compared to the KEN SHE participants.
  • - Results indicated that a single dose of either HPV vaccine effectively induced immune responses in young girls, suggesting it may be sufficient for protection, similar to the responses seen in older women who had received a single
View Article and Find Full Text PDF

Background: Although children aged <1 year have a relatively high rate of venous thromboembolism (VTE) compared to older children, most have additional prothrombotic risk factors. Unprovoked VTE is rare, and little is known about this population, particularly the risk of recurrent VTE.

Objectives: We aimed to determine the rate of recurrent VTE in infants with prior unprovoked VTE and evaluate long-term, end-organ outcomes for infants with renal and intracranial vein thrombosis.

View Article and Find Full Text PDF

Despite the growing number of pediatric antithrombotic clinical trials, standardized safety and efficacy outcome definitions for pediatric venous thromboembolism (VTE) clinical trials have not been updated since 2011. Many recent trials have adapted the recommended definitions, leading to heterogeneity in outcomes and limiting our ability to compare studies. The International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (SSC) on Pediatric and Neonatal Thrombosis and Hemostasis organized a Task Force to update the efficacy and safety outcome definitions for pediatric VTE clinical trials.

View Article and Find Full Text PDF

Objectives: This cross-sectional survey aimed to explore associations between age of menarche, early sexual debut and high-risk sexual behaviour among urban Tanzanian schoolgirls.

Methods: Secondary schoolgirls aged 17-18 years from Mwanza, Tanzania, participated in structured face-to-face questionnaire-based interviews, conducted by nurses and clinicians. Age of menarche was evaluated in categories of 11-12, 13-14, 15-16 or ≥17 years.

View Article and Find Full Text PDF

Background: Unprovoked venous thromboembolism (VTE) is rare in pediatrics. Current recommendations for anticoagulation duration after unprovoked VTE differ for pediatric and adult populations.

Objectives: This single-center, retrospective cohort study aimed to determine the incidence rate of recurrent VTE in children and adolescents with unprovoked VTE, evaluate the potential risk factors for recurrence, and describe the anticoagulation regimens and bleeding in this population.

View Article and Find Full Text PDF

Objective: As part of the Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls (DoRIS; NCT02834637), the current study is one of the first to evaluate the financial and economic costs of the national rollout of an HPV vaccination program in school-aged girls in sub-Saharan Africa and the potential costs associated with a single dose HPV vaccine program, given recent evidence suggesting that a single dose may be as efficacious as a two-dose regimen.

Methods: The World Health Organization's (WHO) Cervical Cancer Prevention and Control Costing (C4P) micro-costing tool was used to estimate the total financial and economic costs of the national vaccination program from the perspective of the Tanzanian government. Cost data were collected in 2019 via surveys, workshops, and interviews with local stakeholders for vaccines and injection supplies, microplanning, training, sensitization, service delivery, supervision, and cold chain.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined COVID-19 vaccine acceptance among healthcare workers in Kambia (Sierra Leone), Goma (DR Congo), and Masaka (Uganda) using questionnaires from April to October 2021.
  • Despite 81.8% of the 543 participants expressing concerns about vaccines, 89.7% recognized their significance for managing the pandemic.
  • Vaccine acceptance was high in Kambia and Masaka, with notable hesitancy in Goma primarily due to fears about the vaccines being new and potential side effects, indicating a need for better information and community outreach.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of administering one dose of HPV vaccine compared to historical studies that showed high efficacy with one dose over an 11-year period against HPV16 and HPV18.
  • Researchers conducted the Dose Reduction Immunobridging and Safety Study (DoRIS) in Tanzania involving girls aged 9-14 years, randomly assigning them to receive one, two, or three doses of either a 2-valent or 9-valent HPV vaccine.
  • The primary goal was to analyze the antibody responses after one dose and determine if these responses were comparable to those found in previous trials, applying statistical methods to assess non-inferiority of immune responses.
View Article and Find Full Text PDF

Background: An estimated 15% of girls aged 9-14 years worldwide have been vaccinated against human papillomavirus (HPV) with the recommended two-dose or three-dose schedules. A one-dose HPV vaccine schedule would be simpler and cheaper to deliver. We report immunogenicity and safety results of different doses of two different HPV vaccines in Tanzanian girls.

View Article and Find Full Text PDF

Venous thromboembolism (VTE) affects up to 25% of individuals with sickle cell disease (SCD), but risk factors are not well characterized. We sought to measure the prevalence of VTE among SCD patients in our health system and to describe the relationship between medical history, biological sex, and VTE. We performed a retrospective chart review of SCD patients who visited an outpatient hematology clinic within Penn Medicine between June 2014 and June 2019.

View Article and Find Full Text PDF

Purpose Of Review: To provide an update regarding what is known about thrombotic events and thromboprophylaxis in critically ill children with SARS-CoV-2 infection.

Recent Findings: Pediatric patients with SARS-CoV-2 generally have mild illness; however, intensive care is required in about 20-30% of hospitalized children with COVID-19 and an even higher proportion in those with MIS-C. Increased rates of thrombosis have been observed in adults hospitalized with COVID-19, and clinical trials have attempted to optimize thromboprophylaxis.

View Article and Find Full Text PDF
Article Synopsis
  • Direct oral anticoagulants (DOACs) are becoming increasingly viable options for treating and preventing blood clots in children, thanks to new trials and the recent approval of drugs like dabigatran and rivaroxaban for pediatric use.
  • Despite the growing adult data, there is still a lack of concrete real-world evidence on how well these drugs work for children who don’t fit the profiles used in clinical trials, raising concerns about their use in certain cases.
  • The review highlights the specific data relevant to pediatrics, identifies areas needing more research, and discusses important practical considerations for effectively using DOACs in pediatric patients.
View Article and Find Full Text PDF

Central venous catheters (CVC) are the most significant risk factor for pediatric venous thromboembolism (VTE). After an index CVC-associated VTE (CVC-VTE), the role of secondary prophylaxis for subsequent CVC placement is uncertain. Aims of this single-center retrospective study were to evaluate the efficacy of secondary prophylaxis for patients with a prior CVC-VTE and identify risk factors associated with recurrent VTE in patients less than 19 years with an index CVC-VTE between 2003 and 2013.

View Article and Find Full Text PDF
Article Synopsis
  • Ichthyosis follicularis, atrichia, and photophobia syndrome (IFAP) is a rare X-linked disorder caused by changes in the MBTPS2 gene, leading to various health issues.
  • Researchers presented a case of a patient with multiple complications including skin and hair issues, heart and kidney problems, and chronic diarrhea, linked to a novel MBTPS2 variant identified through exome sequencing.
  • The study demonstrated that the identified variant disrupts normal cellular functions, contributing to the spectrum of symptoms associated with BRESHECK syndrome, including blood issues and bone marrow fibrosis.
View Article and Find Full Text PDF

Cervical cancer is the leading cause of cancer-related morbidity and mortality in many sub-Saharan African (SSA) countries, including Tanzania. Most cervical cancer cases worldwide are attributable to infection of the cervix with Human Papillomavirus (HPV), a vaccine-preventable sexually transmitted infection (STI). Over the past 10 years, we have conducted a programme of HPV research in pre-adolescents and adolescents in Mwanza, the second-largest city in Tanzania, which is situated in a malaria-endemic region.

View Article and Find Full Text PDF

X-linked myotubular myopathy (XLMTM) is a rare congenital myopathy characterized by profound hypotonia and poor respiratory effort at birth. The condition is associated with multiple morbidities including chronic respiratory insufficiency, feeding tube dependence, and rarely, vitamin K deficiency leading to bleeding and coagulopathy. We report a case of a 6-month-old boy with X-linked myotubular myopathy who experienced a fatal intracranial hemorrhage due to vitamin K deficiency without prior clinical evidence of cholestasis or micronutrient deficiency.

View Article and Find Full Text PDF

Background: The multi-dose regimen is a known barrier to successful human papillomavirus (HPV) vaccination. Emerging evidence suggests that one vaccine dose could protect against HPV. While there are clear advantages to a single dose schedule, beliefs about vaccine dosage in low and middle income countries (LMICs) are poorly understood.

View Article and Find Full Text PDF